BufexamacCAS# 2438-72-4 |
- Risedronate Sodium
Catalog No.:BCC2501
CAS No.:115436-72-1
- Verteporfin
Catalog No.:BCC3690
CAS No.:129497-78-5
- Methylcobalamin
Catalog No.:BCC5188
CAS No.:13422-55-4
- Miglustat hydrochloride
Catalog No.:BCC5186
CAS No.:210110-90-0
- Sulfasalazine
Catalog No.:BCC2545
CAS No.:599-79-1
- SC 144
Catalog No.:BCC1171
CAS No.:895158-95-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 2438-72-4 | SDF | Download SDF |
| PubChem ID | 2466 | Appearance | Powder |
| Formula | C12H17NO3 | M.Wt | 223.27 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Bufexamic acid | ||
| Solubility | DMSO : ≥ 100 mg/mL (447.89 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-(4-butoxyphenyl)-N-hydroxyacetamide | ||
| SMILES | CCCCOC1=CC=C(C=C1)CC(=O)NO | ||
| Standard InChIKey | MXJWRABVEGLYDG-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Bufexamac is a COX inhibitor used as an anti-inflammatory agent.
Target: COX
Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Bufexamac is a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10). Treatment of peripheral blood mononuclear cells with bufexamac inhibits the secretion of IFN-α [1]. Bufexamac is a frequent and relevant contact sensitizer. Bufexamac is a non-steroidal anti-inflammatory drug [2]. References: | |||||
Bufexamac Dilution Calculator
Bufexamac Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.4789 mL | 22.3944 mL | 44.7888 mL | 89.5776 mL | 111.9721 mL |
| 5 mM | 0.8958 mL | 4.4789 mL | 8.9578 mL | 17.9155 mL | 22.3944 mL |
| 10 mM | 0.4479 mL | 2.2394 mL | 4.4789 mL | 8.9578 mL | 11.1972 mL |
| 50 mM | 0.0896 mL | 0.4479 mL | 0.8958 mL | 1.7916 mL | 2.2394 mL |
| 100 mM | 0.0448 mL | 0.2239 mL | 0.4479 mL | 0.8958 mL | 1.1197 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.
- (-)-alpha-Pinene
Catalog No.:BCC8295
CAS No.:2437-95-8
- 3,5-Cycloergosta-6,8(14),22-triene
Catalog No.:BCN5100
CAS No.:24352-51-0
- S-(5'-Adenosyl)-L-methionine chloride
Catalog No.:BCN2229
CAS No.:24346-00-7
- Apamin
Catalog No.:BCC7141
CAS No.:24345-16-2
- 6-Amino-1-methyluracil
Catalog No.:BCC8757
CAS No.:2434-53-9
- Nagilactone C
Catalog No.:BCN4040
CAS No.:24338-53-2
- Tricosanoic acid
Catalog No.:BCN5394
CAS No.:2433-96-7
- 9-Fluorenylmethanol
Catalog No.:BCC2801
CAS No.:24324-17-2
- Cephalotaxine
Catalog No.:BCN2957
CAS No.:24316-19-6
- Scandine
Catalog No.:BCN5099
CAS No.:24314-59-8
- Hesperidin methylchalcone
Catalog No.:BCN8125
CAS No.:24292-52-2
- Mycophenolic acid
Catalog No.:BCC4803
CAS No.:24280-93-1
- L-(-)-Fucose
Catalog No.:BCN8326
CAS No.:2438-80-4
- pep2m
Catalog No.:BCC5782
CAS No.:243843-42-7
- pep4c
Catalog No.:BCC5783
CAS No.:243843-43-8
- Glycoside L-F2
Catalog No.:BCN2158
CAS No.:243857-99-0
- 5-Iodotubercidin
Catalog No.:BCC1312
CAS No.:24386-93-4
- Kynurenic acid sodium salt
Catalog No.:BCC7754
CAS No.:2439-02-3
- Ethyl 4-methoxycinnamate
Catalog No.:BCN5028
CAS No.:24393-56-4
- Cnicin
Catalog No.:BCN8546
CAS No.:24394-09-0
- TCS 401
Catalog No.:BCC2469
CAS No.:243967-42-2
- TAK-242 S enantiomer
Catalog No.:BCC1978
CAS No.:243984-10-3
- TAK-242
Catalog No.:BCC1977
CAS No.:243984-11-4
- beta-D-glucose
Catalog No.:BCN8171
CAS No.:492-61-5
Bufexamac ameliorates LPS-induced acute lung injury in mice by targeting LTA4H.[Pubmed:27126280]
Sci Rep. 2016 Apr 29;6:25298.
Neutrophils play an important role in the occurrence and development of acute lung injury (ALI). Leukotriene B4 (LTB4), a hydrolysis product of epoxide leukotriene A4 (LTA4) catalyzed by LTA4 hydrolase (LTA4H), is one of the most potent chemoattractants for neutrophil. Bufexamac is a drug widely used as an anti-inflammatory agent on the skin, however, the mechanism of action is still not fully understood. In this study, we found Bufexamac was capable of specifically inhibiting LTA4H enzymatic activity and revealed the mode of interaction of Bufexamac and LTA4H using X-ray crystallography. Moreover, Bufexamac significantly prevented the production of LTB4 in neutrophil and inhibited the fMLP-induced neutrophil migration through inhibition of LTA4H. Finally, Bufexamac significantly attenuated lung inflammation as reflected by reduced LTB4 levels and weakened neutrophil infiltration in bronchoalveolar lavage fluid from a lipopolysaccharide-induced ALI mouse model. In summary, our study indicates that Bufexamac acts as an inhibitor of LTB4 biosynthesis and may have potential clinical applications for the treatment of ALI.
Allergic contact dermatitis to topical preparations of bufexamac.[Pubmed:22881467]
Australas J Dermatol. 2012 Aug;53(3):207-10.
In Australia Bufexamac is mainly used for pharmacist-initiated local treatment of various dermatoses. The European Medicines Agency's Committee for Medicinal Products for Human Use recently recommended that marketing authorisation for Bufexamac-containing preparations be revoked throughout the European Union because of the risk of severe allergic contact dermatitis. We retrospectively reviewed the patch test database at the Skin and Cancer Foundation Inc. and identified 19 cases of positive reactions to Bufexamac (5% petrolatum) from 451 people patch tested. The Bufexamac reaction was deemed relevant to the presenting dermatitis in 13 of 19 (68%) patients. Bufexamac allergic contact dermatitis is under-reported in the English literature. We wish to emphasise the severity and the unusually polymorphic eruptions observed in some of the cases. Clinicians should consider the possibility of allergic contact dermatitis to Bufexamac-containing preparations in all patients where there is a history of exposure, even if used for only a short time.
